Tausif Butt
President chez Idorsia Pharmaceuticals US, Inc.
Profil
Tausif Butt is currently the President & General Manager at Idorsia Pharmaceuticals US, Inc. Prior to this, he was the Senior Vice President-Latin America at AstraZeneca PLC from 2019 to 2021 and the Chief Operating Officer & Executive Vice President at ChemoCentryx, Inc. from 2021 to 2022.
Mr. Butt has a graduate degree from Imperial College London and an undergraduate degree from the University of Brighton.
Postes actifs de Tausif Butt
| Sociétés | Poste | Début |
|---|---|---|
| Idorsia Pharmaceuticals US, Inc. | President | 05/09/2023 |
Anciens postes connus de Tausif Butt
| Sociétés | Poste | Fin |
|---|---|---|
| CHEMOCENTRYX, INC. | Chief Operating Officer | 20/10/2022 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2021 |
Formation de Tausif Butt
| Imperial College London | Graduate Degree |
| University of Brighton | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
| Idorsia Pharmaceuticals US, Inc. |
